Amyloid in human islets of langerhans: Immunologic evidence that islet amyloid polypeptide is modified in amyloidogenesis

Pancreas

Volumn 21, Issue 2, 2000, Pages 212-218

  Ma, Z ^a   Westermark, P ^a,b   Westermark, G T ^a,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amyloid; Antigen retrieval; Glycation; Immunohistochemistry; Islet amyloid polypeptide; Protein modification; Type II diabetes mellitus

Indexed keywords

AMYLIN;

AMINO ACID COMPOSITION; AMYLOIDOSIS; ANTIGEN RETRIEVAL; ARTICLE; CONFORMATIONAL TRANSITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION;

AMYLOID; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; GLYCOSYLATION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ISLETS OF LANGERHANS; MICROSCOPY, ELECTRON;

EID: 0033864076     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200008000-00015     Document Type: Article

References (39)

1. Pathogenesis of NIDDM: A balanced overview
2. Islet amyloid: A long-recognized but underappreciated pathological feature of Type 2 diabetes
3. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells
4. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients
5. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
6. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-size toxic amyloid particles
7. Effects of beta cell granule components on human islet amyloid polypeptide fibril formation
8. Alternative conformation of amyloidogenic proteins govern their behavior
9. Mutations and off-pathway aggregation of proteins
10. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation
11. Interspecies sequence variations affect the kinetics and thermodynamics of amyloid formation: Peptide models of pancreatic amyloid
12. Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin-dependent) diabetic and nondiabetic individuals
13. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes
14. Islet amyloid polypeptide (IAPP) and pancreatic islet amyloid deposition in diabetic and non-diabetic patients
15. Localisation of islet amyloid polypeptide and its carboxy terminal flanking peptide in islets of diabetic man and monkey
16. Islet amyloid polypeptide: Demonstration of mRNA in human pancreatic islets by in situ hybridization in islets with and without amyloid deposits
17. Altered immunoreactivity of islet amyloid polypeptide (IAPP) may reflect major modifications of the IAPP molecule in amyloidogenesis
18. Mast cells in rat gastrointestinal mucosa
19. Islet amyloid polypeptide in the rabbit and European hare: Studies on its relationship to amyloidogenesis
20. The use of avidin-biotin interaction in immunoenzymatic techniques
21. Unmasking antigen determinants in amyloid
22. Immunohistochemical study of cerebral amyloid angiopathy. II. Enhancement of immunostaining using formic acid pretreatment of tissue sections
23. The association of amyloid P-component (AP) with the amyloid fibril: An updated method for amyloid fibril protein isolation
24. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone
25. On the binding of Congo red by amyloid
26. Decreased interaction of fibronectin, type IV collagen, and heparin due to nonenzymatic glycation. Implication for diabetes mellitus
27. A microassay for protein glycation based on the periodate method
28. The complete amino acid sequence of a prototype immunoglobulin-λ light-chain-type amyloid-fibril protein AR
29. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas
30. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging
31. Glycation of insulin in the islets of Langerhans of normal and diabetic animals
32. Advanced glycation end products contribute to amyloidosis in Alzheimer disease
33. Advanced Maillard reaction end products are associated with Alzheimer disease pathology
34. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide
35. β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis
36. Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma
37. Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide
38. Quantitative immunohistochemical analysis of islet amyloid polypeptide (IAPP) in normal, impaired glucose tolerant and diabetic cats